Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the FDA approval of nivolumab at a fixed dose across all of the PD-1 inhibitor’s monotherapy indications.

Related Content:

OncLive TVImmuno-Oncology
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer